Form 4 Health Catalyst Inc: Simeon Kohl (Director, CEO) For: 14 September
This article reports on a Form 4 filing for Health Catalyst Inc, detailing transactions made by Simeon Kohl, who serves as a Director and CEO of the company. The filing is specifically for September 14. The company's stock, HCAT, is noted as having increased by 11.03%.
Form 144 HEALTH CATALYST INC For: 14 November By Investing.com
This article announces the filing of Form 144 for Health Catalyst Inc. (HCAT) on November 14. The company's stock, HCAT, is noted to be up 11.03%. The article provides a brief update on this financial filing from Investing.com.
Under a trading plan, Health Catalyst (HCAT) counsel Benjamin Landry sells 99,478 shares.
Health Catalyst (HCAT) General Counsel Benjamin Landry sold a total of 99,478 common shares in two transactions on November 11 and November 12, 2026, for approximately $141,000. These sales were executed pursuant to a pre-arranged Rule 10b5-1 trading plan adopted on August 12, 2026. After these transactions, Landry's direct holdings in Health Catalyst common stock stand at 251,894 shares.
Form 144 HEALTH CATALYST INC For: 13 November By Investing.com
This article from Investing.com announces the filing of Form 144 for HEALTH CATALYST INC on November 13, 2026. Form 144 is a notice of the intent to sell restricted securities, indicating potential insider activity for the company. The article provides a brief mention of this filing without further details on the specific transaction.
Form 144 HEALTH CATALYST INC For: 13 November By Investing.com
This article reports on the filing of Form 144 for HEALTH CATALYST INC, dated November 13. Form 144 is a notice of the intent to sell restricted securities. The brief notice indicates a transaction involving HCAT, which saw a +11.03% change.
Officer Benjamin Landry proposes selling 29,478 Health Catalyst (HCAT) shares.
Health Catalyst, Inc. officer Benjamin Landry has proposed selling 29,478 common shares, valued at $42,153.54, with an approximate sale date of November 12, 2026. These shares were acquired through the vesting of restricted stock units. The filing also notes prior 10b5-1 sales by Landry, including 70,000 shares on November 11, 2026, and 13,167 shares on September 1, 2026.
Officer Benjamin Landry reports 99,478 shares for sale at Health Catalyst (HCAT).
Health Catalyst officer Benjamin Landry has reported his intent to sell 99,478 common shares of HCAT, with an approximate sale date of November 11, 2026, and an aggregate market value of $143,248.32. These shares were acquired through restricted stock unit vesting between February 25 and September 1, 2026. The filing also notes a previous sale by Landry of 13,167 common shares on September 1, 2026, for gross proceeds of $22,431.30.
SoundHound AI, Health Catalyst, and Toast shares are falling, what you need to know
SoundHound AI, Health Catalyst, and Toast shares experienced declines following a hotter-than-expected October consumer inflation report and hawkish commentary from the Federal Reserve. Federal Reserve Governor Christopher Waller indicated a likely December rate hike, possibly 50 basis points, to combat persistent price pressures, which disproportionately affected growth-oriented technology stocks due to their long-duration cash flows. Health Catalyst, in particular, has seen significant volatility and a substantial year-to-date decline, exacerbated by a weak third-quarter revenue forecast and lowered full-year guidance.
Health Catalyst, Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For Next Year
Health Catalyst, Inc. (NASDAQ:HCAT) reported third-quarter results that saw an unexpected statutory profit of US$0.53 per share, significantly improving on analyst forecasts for losses, despite revenues of US$56m being in line with expectations. Following these results, analysts project a 24% revenue decline to US$205.7m in 2027 but anticipate a substantial 74% reduction in losses to US$0.69 per share. The consensus price target remained unchanged at US$1.77, suggesting that despite the projected revenue decrease, the company's performance is largely meeting market expectations.
What Health Catalyst (HCAT) Said on Its Q3 Earnings Call
Health Catalyst (HCAT) reported third-quarter revenue and adjusted EBITDA above guidance, but acknowledged ongoing challenges with client churn and cost pressures. The company reaffirmed its full-year 2026 outlook and is prioritizing client retention and cost alignment under its new CEO, Simeon Kohl. Margins were pressured by services costs and higher employee medical claims, though operating expenses saw a reduction.
Health Catalyst (NASDAQ:HCAT) exceeds Q3 2026 expectations
Health Catalyst (NASDAQ:HCAT) surpassed Wall Street's Q3 2026 revenue expectations, reaching $56.28 million, despite a 26.3% year-on-year decline. The company also beat adjusted EPS estimates with a loss of $0.03 per share and reaffirmed its full-year revenue outlook of $247.5 million. However, long-term revenue growth has been weak, and customer acquisition efficiency showed a negative payback period, indicating challenges in a competitive market.
Health Catalyst Reports Third Quarter 2026 Results
Health Catalyst, Inc. reported its financial results for the third quarter of 2026, exceeding its revenue and Adjusted EBITDA guidance. The company reaffirmed its full-year outlook, with a focus on client retention and generating durable, profitable revenue. Key financial metrics showed a year-over-year decrease in total revenue and gross profit, largely due to the divestiture of its Vitalware business and migration headwinds, but net income saw a significant increase due to a gain on the sale of Vitalware.
Health Catalyst (HCAT) Reports Q3 Loss, Beats Revenue Estimates
Health Catalyst (HCAT) reported a Q3 loss of $0.03 per share, missing the Zacks Consensus Estimate of a $0.02 loss, but surpassed revenue estimates with $56.28 million. Despite beating revenue expectations in four of the last four quarters, the company's shares have fallen 33.5% year-to-date, contrasting with the S&P 500's gain. The stock currently holds a Zacks Rank #3 (Hold), indicating an expected in-line performance with the market in the near future.
Health Catalyst Q3 2026 Earnings Call Transcript
Health Catalyst (NASDAQ: HCAT) reported strong Q3 2026 financial results, exceeding revenue and adjusted EBITDA guidance. The company reaffirmed its full-year 2026 outlook and highlighted a strengthened financial foundation after the Vitalware divestiture, leaving them debt-free with $79 million in cash. New CEO Simeon Kohl outlined four key priorities: improving client retention, aligning costs with revenue, simplifying operations, and enhancing execution consistency, all aimed at achieving sustainable, profitable growth.
Health Catalyst (NASDAQ:HCAT) exceeds Q3 2026 expectations
Health Catalyst (NASDAQ:HCAT) exceeded Wall Street's revenue expectations for Q3 2026, reaching $56.28 million, despite a 26.3% year-on-year decline. The company also reported a non-GAAP loss of $0.03 per share, which was better than analyst estimates. However, its long-term revenue growth remains weak, and full-year EBITDA guidance fell slightly short of expectations.
A $65.9M sale gain feeds into Health Catalyst (HCAT)'s Q3 profit as revenue falls.
Health Catalyst (HCAT) reported a Q3 2026 net income of $40.5 million, a significant improvement from a $22.2 million loss in Q3 2025, primarily driven by a $65.9 million gain from the sale of its Vitalware business. Despite this, total revenue for the quarter fell by 26% to $56.3 million due to the Vitalware divestiture, discontinuation of certain low-margin professional services, and customer churn related to the migration from its DOS platform to Health Catalyst Ignite. The company's Adjusted EBITDA also decreased to $0.8 million from $12.0 million in the prior year, largely reflecting the divestiture of the profitable Vitalware segment.
Health Catalyst earnings beat by $0.58, revenue topped estimates
Health Catalyst (NASDAQ: HCAT) reported strong third-quarter results, beating analyst estimates with an EPS of $0.53, significantly higher than the expected $-0.05. The company's revenue also surpassed expectations, reaching $56.2 million against a consensus of $55.44 million. Despite the positive earnings, Health Catalyst's stock has seen a decline of -13.29% in the last three months and -49.32% in the last 12 months, though its financial health is rated as "good performance" by InvestingPro.
Health Catalyst, Inc. (HCAT) Seasonal returns chart
The article provides a seasonal returns chart for Health Catalyst, Inc. (HCAT), showing the average monthly price return from 2019 to 2026. It indicates a real-time delayed quote for HCAT at 1.6900 USD, a decrease of 5.59% at market close on October 30.
Health Catalyst, Inc. (HCAT) Seasonal Returns Chart - Yahoo Finance
This article displays the historical seasonality chart for Health Catalyst, Inc. (HCAT), showing average monthly price returns from 2019 to 2026. As of October 29, the stock was trading at 1.7900 USD, down 0.56%. The page also provides various financial data categories for HCAT.
Health Catalyst, Inc Estimates – NASDAQ:HCAT
This page provides financial actuals and estimates for Health Catalyst, Inc (NASDAQ: HCAT) on TradingView. Users can explore reported financial data and analyst estimates across various statements and metrics, compare actual results with average, high, and low estimates, and visualize trends over time. The information includes income statement, balance sheet, and cash flow data on both an annual and quarterly basis.
Health Catalyst to Announce Third Quarter 2026 Operating Results and Host Conference Call on Thursday, November 5, 2026
Health Catalyst, Inc. (Nasdaq: HCAT) will release its third quarter 2026 operating results after market close on Thursday, November 5, 2026. The company will also host a conference call at 5:00 pm ET on the same day to discuss the results. Details for accessing the conference call via dialing or live audio webcast are provided, with a replay available online for 90 days.
Health Catalyst, Inc. Estimates – GETTEX:2YP
This article provides an overview of Health Catalyst, Inc. (GETTEX:2YP) on TradingView, focusing on its financial data and analyst estimates. Users can explore reported financial data, compare actual results with average, high, and low estimates, and visualize trends over time across income statements, balance sheets, and cash flow statements.
Health Catalyst to Announce Third Quarter 2026 Operating Results and Host Conference Call on Thursday, November 5, 2026
Health Catalyst, Inc. (Nasdaq: HCAT) will release its third quarter 2026 operating results after market close on Thursday, November 5, 2026. The company will also host a conference call at 5:00 pm ET on the same day to discuss the results, with details provided for both U.S. and international participants, as well as a live audio webcast. A replay will be available online for approximately 90 days following the call.
Health Catalyst (HCAT): Buy, Sell, or Hold Post Q2 Earnings?
Despite a recent 48.7% surge in stock price over six months, analysts recommend caution for Health Catalyst (HCAT) due to declining billings, low gross margins, and long customer acquisition payback periods. The company's fundamentals are considered shaky, making its optically cheap valuation risky. Instead, the article suggests looking for more robust investment opportunities.
Health Catalyst stock falls 2.24 percent as CEO reset unfolds
Health Catalyst stock fell 2.24 percent on September 29, 2026, as the company navigates a CEO transition and operates with a smaller business after divesting Vitalware. Despite the stock drop, the healthcare intelligence company reported Q2 2026 revenue of $70.49 million, exceeding its guidance, and reduced its debt by $160 million. Analysts maintain a "Hold" consensus on the stock, with an average 12-month price target of $2.45.
Health Catalyst, Inc. (HCAT) Latest Stock News & Headlines - Yahoo Finance
This Yahoo Finance page provides the latest news and headlines for Health Catalyst, Inc. (HCAT), including stock performance data, analyst opinions, and company announcements. It summarizes recent articles discussing skepticism about certain software and unprofitable stocks, HCAT's fair value changes, board appointments, and leadership changes. The article also presents HCAT's trailing total returns compared to the S&P 500.
Wells Fargo raises Health Catalyst price target to $1.75
Wells Fargo analyst Stan Berenshteyn has raised the price target for Health Catalyst (NASDAQ: HCAT) to $1.75 from $1, while maintaining an Equal-Weight rating. This adjustment reflects a revised valuation outlook for the healthcare data analytics provider. The article also mentions Health Catalyst's participation in the Truist Securities Healthcare Disruptors & Digital Health Conference, where CEO Ben Albert will discuss AI ROI in Healthcare.
Health Catalyst Appoints Simeon Kohl CEO as Ben Albert Moves to Chief Business Officer
Health Catalyst has appointed Simeon Kohl as its new Chief Executive Officer and President, effective September 14, succeeding Ben Albert who transitions to Chief Business Officer. Kohl, with over 20 years of healthcare experience, including leading Performant Healthcare before its acquisition, also joins the Health Catalyst board. This leadership change occurs as Health Catalyst continues to develop AI-driven technology and services to improve health system performance.
Health Catalyst (HCAT) Stock Fair Value Falls As Analysts Cut Targets On Growth Risks
Analysts have revised Health Catalyst's (HCAT) fair value down from approximately US$2.10 to US$1.83 per share, reflecting increased caution due to growth risks, churn, and divestitures. While some analysts maintain a Neutral stance, others have downgraded the stock to Hold and reduced price targets. This shift highlights concerns about the durability of growth in its health technology offerings and ongoing transformation efforts.
Health Catalyst stock trades near lows as small-cap sentiment weakens
Health Catalyst (HCAT) stock is trading near its lows at around USD 1.79, reflecting weakened small-cap sentiment and investor caution. Despite recent revenue growth, the company continues to report net losses, leading analysts to avoid it due to profitability concerns. Its low valuation of 0.6 times forward price-to-sales highlights market skepticism given its loss-making status and the current challenging environment for unprofitable growth stocks.
Simeon Kohl Bought 118% More Shares In Health Catalyst
Health Catalyst CEO Simeon Kohl recently purchased US$105k worth of company stock, increasing his holdings by 118%. This follows other insider buying activity over the past year, with insiders purchasing more shares than they sold, at an average price higher than the current market price. While the company has not been profitable in the last twelve months, these insider transactions suggest a positive outlook on the stock, despite relatively low overall insider ownership.
Health Catalyst gets a new chief after he led a healthcare company through a roughly $670 million sale.
Health Catalyst has appointed Simeon Kohl as its new Chief Executive Officer and President, effective September 14, 2026. Kohl previously led Performant Healthcare through a strategic transformation culminating in its sale for approximately $670 million. Current CEO Ben Albert will transition to Chief Business Officer, having overseen the company's shift towards AI-forward healthcare intelligence and the divestiture of Vitalware to strengthen its balance sheet.
Health Catalyst Strengthens Its Board with the Appointment of Tami Reller
Health Catalyst announced the appointment of Tami Reller to its board of directors, effective October 1, 2026. Reller will serve as audit chair and a member of the compensation committee, bringing extensive experience in finance, technology, and healthcare delivery. This appointment aligns with Health Catalyst's strategic focus on advancing its AI-forward healthcare intelligence, following Simeon Kohl's new role as CEO.
Health Catalyst Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Health Catalyst, Inc. announced the grant of 2,747,385 restricted stock units (RSUs) to Simeon Kohl, their newly appointed Chief Executive Officer and President, effective September 14, 2026. These inducement awards are part of the Company's 2026 Employment Inducement Incentive Plan, in accordance with Nasdaq Listing Rule 5635(c)(4). A portion of the RSUs will vest in September 2027, with the remainder vesting quarterly thereafter, contingent on Mr. Kohl's continued employment.
Health Catalyst Appoints Simeon Kohl As CEO And President
Health Catalyst has appointed Simeon Kohl as its new CEO and President, effective September 14, 2026. Kohl, who has over 20 years of healthcare experience and previously led Performant Healthcare, will succeed Ben Albert. Albert will transition to Chief Business Officer, focusing on strategic priorities alongside Kohl, who is expected to enhance growth and operational performance for the AI-forward healthcare intelligence company.
Health Catalyst appoints Tami Reller to board a...
Health Catalyst has appointed Tami Reller to its board of directors, effective October 1, 2026, where she will serve as audit chair and join the compensation committee. This strategic move aims to support the company's next phase of growth, focusing on AI-driven healthcare intelligence under new CEO Simeon Kohl. Reller's extensive experience in healthcare and technology, including her past roles at Microsoft and UnitedHealth Group, is expected to help Health Catalyst deliver impactful technology solutions.
Health Catalyst Grants 2.7 Million RSUs to New CEO Simeon Kohl and Discloses Open Market Share Purchases
Health Catalyst (HCAT) granted 2.7 million Restricted Stock Units (RSUs) to its new CEO, Simeon Kohl, as part of his employment agreement, effective September 14, 2026. This RSU grant is under the company's 2026 Employment Inducement Incentive Plan, with a portion vesting on September 14, 2027, and the remainder in quarterly installments. Additionally, Kohl demonstrated confidence in the company by purchasing 59,000 shares of Health Catalyst common stock on the open market.
Health Catalyst Strengthens Its Board with the Appointment of Tami Reller
Health Catalyst, Inc. announced the appointment of Tami Reller to its board of directors, effective October 1, 2026. Reller will serve as audit chair and a member of the compensation committee, bringing extensive experience in healthcare and technology, particularly in finance, growth, operations, marketing, and consumer experience. Her appointment comes as the company continues to advance its AI-forward healthcare intelligence strategy under new leadership.
The Escalator: Inizio, Health Catalyst, Eversana and more
This article, "The Escalator," details recent significant personnel changes across the pharmaceutical, biotech, and medical marketing sectors. It covers new hires, executive promotions, board appointments, and notable departures at various companies including Inizio, Eversana, Health Catalyst, and Flare Therapeutics. The piece highlights the dynamic movement of leadership within the healthcare industry.
Equity grant lifts Health Catalyst (HCAT) director to 185K shares
Health Catalyst (HCAT) director Julie Larson-Green received an award of 9,766 restricted stock units (RSUs), which fully vested on September 1, 2026. This equity grant increased her direct holdings to 185,101 shares of common stock. The award was granted at no cash purchase price under the company’s 2019 Stock Option and Incentive Plan.
Health Catalyst appoints new CEO
Health Catalyst has appointed Simeon Kohl as its new CEO, making him the company's third chief executive this year. Kohl, who previously led Performant Healthcare, will take over on September 14, succeeding Ben Albert. The appointment comes as Health Catalyst focuses on artificial intelligence and navigates revenue declines, including a 13% drop in the second quarter after selling its Vitalware revenue cycle unit.
Mandatory tax sale by Health Catalyst (HCAT) CEO
Health Catalyst (HCAT) CEO Albert Benjamin sold 35,244 shares of common stock on September 10, 2026, for $1.6747 per share. This was a mandatory "sell-to-cover" transaction to satisfy tax withholding obligations related to the vesting of Restricted Stock Units, not a discretionary trade. Following the sale, Benjamin directly holds 1,388,406 shares of common stock.
Investor group asks for clearer plan at Health Catalyst (NASDAQ: HCAT)
Palogic-affiliated investors, holding a 7.1% stake in Health Catalyst (HCAT), have submitted an amended Schedule 13D filing urging the company's board to provide a clearer forward-looking business plan. The group, which acquired its shares for approximately $11.79 million, is requesting more detailed disclosure on R&D costs, enhanced revenue metrics, capital allocation strategies, and a defined path to profitable growth following the VitalWare sale. They emphasized their concerns in a letter sent to Health Catalyst's board on September 4, 2026.
Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President
Health Catalyst, Inc. has announced the appointment of Simeon Kohl as its new Chief Executive Officer and President, effective September 14, 2026. Kohl, previously CEO of Performant Healthcare, brings over 20 years of experience in healthcare leadership. Current CEO Ben Albert will transition to Chief Business Officer, a strategic move aimed at enhancing the company's growth and operational performance, particularly in AI-forward healthcare intelligence.
Health Catalyst appoints Simeon Kohl as new CEO
Health Catalyst (HCAT) has appointed Simeon Kohl as its new CEO and president, effective September 14, 2026, replacing Ben Albert, who will transition to chief business officer. Kohl brings extensive experience in healthcare technology, having previously led Performant Healthcare through a successful transformation and sale. The company also adopted a new inducement equity plan to support recruitment and M&A, reinforcing its strategic focus on AI-driven growth and a strengthened balance sheet.
Health Catalyst names Simeon Kohl as new CEO By Investing.com
Health Catalyst Inc. has appointed Simeon Kohl as its new Chief Executive Officer, President, and a member of its Board of Directors, effective September 14. Kohl, who previously led Performant Healthcare through a significant transformation, brings over 20 years of experience in the healthcare sector. Current CEO Ben Albert will transition to Chief Business Officer, continuing to contribute to the company's strategic priorities.
Health Catalyst taps new CEO
Health Catalyst has announced Simeon Kohl as its new President and CEO. This change follows Ben Albert's tenure. The article also mentions other healthcare news, including new insurer entrants, tax law consultations, Epic's AI app connector, and Elevance's raised guidance.
Health Catalyst names Simeon Kohl as new CEO By Investing.com
Health Catalyst Inc. announced the appointment of Simeon Kohl as its new Chief Executive Officer, President, and Board member, effective September 14. Kohl, previously CEO of Performant Healthcare, brings over 20 years of healthcare experience. Current CEO Ben Albert will transition to Chief Business Officer, continuing to work with Kohl on strategic priorities.
Health Catalyst Appoints Simeon Kohl as Chief Executive Officer and President
Health Catalyst, Inc. (Nasdaq: HCAT) has appointed Simeon Kohl as its new Chief Executive Officer and President, effective September 14, 2026. Kohl, who previously led Performant Healthcare through a significant transformation and successful sale, brings over 20 years of healthcare leadership experience. Current CEO Ben Albert will transition to Chief Business Officer, having led the company to focus on AI-forward healthcare intelligence and strengthening its balance sheet through divestitures.
Health Catalyst (HCAT) CEO offloads 321 shares to cover taxes
Health Catalyst (HCAT) CEO Albert Benjamin sold 321 shares of common stock at $1.7036 per share on September 1, 2026. This transaction was not discretionary but was mandated to cover tax withholding obligations from the vesting of Restricted Stock Units. Following this sale, Benjamin directly holds 1,423,650 shares of Health Catalyst common stock.